NewsBenzingaEl enicepatide de Roche cumple con ambos objetivos primarios en el ensayo de fase II, logrando reducciones de glucosa y peso dependientes de la dosis en pacientes con diabetes tipo 2 y obesidad El enicepatide de Roche cumple con ambos objetivos primarios en el ensayo de fase II, logrando reducciones de glucosa y peso dependientes de la dosis en pacientes con diabetes tipo 2 y obesidad Benzinga 2026.09.22 06:15 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target If You Invested $1000 In Ulta Beauty Stock 15 Years Ago, You Would Have This Much Today